Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

A New Course For AMAG: Expanding Feraheme And Moving Beyond Iron

Executive Summary

AMAG is looking to build out its portfolio by in-licensing or acquiring new commercial products that complement its I.V. iron product Feraheme. The company is in negotiations for multiple assets, while at the same time preparing to launch Feraheme into a broader patient population.

You may also be interested in...



Deal Watch: Tax Policy Changes Claiming Victims Already, As Salix/Cosmo Plans Abandoned

Abandoned deals were the order of the week as the Salix/Cosmo breakup followed Novartis’ exit from hepatitis C drug development and a partnership in that space with Enanta. J&J, however, increased its bet on HCV by acquiring Alios, one of several noteworthy buyouts occurring during the week.

AMAG Pursues Expanded Feraheme Strategy Through Lumara Deal

The biotech is acquiring privately held Lumara and its women’s health product Makena in hopes of using the salesforce once it expands the indication for its I.V. iron product Feraheme into that market.

AMAG’s Turnaround Plans Hit A Snag With Feraheme CRL

FDA declined to approve the I.V. iron in a broad patient population and requested another clinical trial to further evaluate safety. The decision gives rival Daiichi more time to penetrate the market with its I.V. iron Injectafer.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS055693

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel